Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Promising strategies to optimize CAR-T therapy in ALL

Sara Ghorashian • 12 Jun 2022
EHA 2022
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia CAR-T

Sara Ghorashian, PhD, MD, FRCP, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, discusses strategies to optimize CAR-T therapy in acute lymphoblastic leukemia (ALL), drawing focus on the potential role of dual-targeting approaches and the importance of improving persistence. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Sara Ghorashian

Exciting updates in ALL and the value of novel immunotherapies
1:11
Exciting updates in ALL and the value of novel immunotherapies
Sara Ghorashian • 11 Dec 2022
Evaluating dual-targeting CD19/22 CAR-T cells in patients with R/R ALL
3:18
Evaluating dual-targeting CD19/22 CAR-T cells in patients with R/R ALL
Sara Ghorashian • 11 Dec 2022
Analysis of real-world outcomes in patients with B-ALL receiving tisagenlecleucel
2:18
Analysis of real-world outcomes in patients with B-ALL receiving tisagenlecleucel
Sara Ghorashian • 11 Dec 2022
Managing relapse after CAR-T therapy in ALL
1:20
Managing relapse after CAR-T therapy in ALL
Sara Ghorashian • 12 Jun 2022

Related Videos

How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
4:56
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
Stephan Stilgenbauer • 16 Oct 2026
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
1:22
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
Marta Coscia • 16 Oct 2026
The content of VJHemOnc is intended for healthcare professionals